Page last updated: 2024-11-08

securinine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

securinine: a quinolizine pseudoalkaloid (not from amino acid) from Securinega suffurutiosa or Securinini nitras [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID442872
CHEMBL ID303062
CHEBI ID9079
SCHEMBL ID892754
MeSH IDM0040788

Synonyms (72)

Synonym
securininum [inn-latin]
(6s,11ar,11bs)-9,10,11,11a-tetrahydro-8h-6,11b-methanofuro(2,3-c)pyrido(1,2-a)azepin-2(6h)-one
nsc 107413
securinine [inn]
2-oxo-2,6,9,10,11,11a-hexahydro-8h-6,11b-methanofuro(2,3-c)pyrido(1,2-a)azepin
securinina [inn-spanish]
BRD-K49071277-001-02-1
BSPBIO_003577
nsc-107413
securinan-11-one
securinine
securinine, (-)-
5610-40-2
(6s,11ar,11bs)-9,10,11,11a-tetrahydro-8h-6,11b-methanofuro[2,3-c]-pyrido[1,2-a]azepin-2(6h)-one
UPCMLD-DP039:001
UPCMLD-DP039
NCGC00142506-01
NCGC00142506-03
KBIO3_002957
SPECTRUM3_001977
SPECTRUM2_000669
SPBIO_000737
SPECTRUM1505334
NCGC00142506-04
STK256368
(6s,11ar,11bs)-9,10,11,11a-tetrahydro-8h-6,11b-methanofuro[2,3-c]pyrido[1,2-a]azepin-2(6h)-one
AKOS000265560
(-)-securinine
CHEMBL303062
chebi:9079 ,
l-securinine
HMS1922D22
(1s,8s,14r)-2-oxa-9-azatetracyclo[6.6.1.0<1,5>.0<9,14>]pentadeca-4,6-dien-3-on e
nsc-758972
pharmakon1600-01505334
nsc758972
dtxcid5025944
dtxsid7045944 ,
tox21_111468
CCG-40031
NCGC00017322-04
NCGC00017322-02
NCGC00017322-05
NCGC00017322-03
unii-g4vs580p5e
securininum
g4vs580p5e ,
securinina
6,10-methanopyrido(1,2-a)azepine-.gamma.9(6h),.alpha.-acetic acid,1,2,3,4,10,10a-hexahydro-10-hydroxy-, .gamma.-lactone
securinine [mi]
securinine [who-dd]
SCHEMBL892754
smr000542846
MLS006011461
AB00643342_02
mfcd03225476
securinine, >=98% (hplc)
rel-(6r,11as,11br)-9,10,11,11a-tetrahydro-8h-6,11b-methanofuro[2,3-c]pyrido[1,2-a]azepin-2(6h)-one
SBI-0207079.P001
HY-N2079
CS-0018584
Q4413415
(a?-securinine
BS-17623
BRD-K49071277-001-03-9
HMS3886H20
S9249
rel-(6s,11ar,11bs)-6,8,9,10,11,11a-hexahydro-2h-6,11b-methanofuro[2,3-c]pyrido[1,2-a]azepin-2-one
(1s,2r,8s)-14-oxa-7-azatetracyclo[6.6.1.01,11.02,7]pentadeca-9,11-dien-13-one
EN300-19767685
(1s,2r,8s)-14-oxa-7-azatetracyclo[6.6.1.0^{1,11}.0^{2,7}]pentadeca-9,11-dien-13-one
6,10-methanopyrido(1,2-a)azepine-gamma9(6h),alpha-acetic acid,1,2,3,4,10,10a-hexahydro-10-hydroxy-, gamma-lactone

Research Excerpts

Overview

Securinine (Sec) is a naturally derived compound separated from the roots of Securinega suffruticosa, which has long been used as a herbal medicine. Allosecurinine is a plant-derived indolicidine securineGA alkaloid shown bioactivity.

ExcerptReferenceRelevance
"Securinine is an alkaloid identified from the roots and leaves of the shrub Flueggea suffruticosa (Pall.) Baill. "( Potential anticancer activities of securinine and its molecular targets.
Chen, QX; Fan, XD; Jiang, JG; Liu, CJ; Zhu, W, 2022
)
2.44
"Allosecurinine is a plant-derived indolicidine securinega alkaloid shown bioactivity."( Synthesis, biological activity and mechanism of action of novel allosecurinine derivatives as potential antitumor agents.
Chen, WM; Dai, W; Hou, W; Huang, H; Huang, LJ; Huang, XH; Lan, JX; Li, XJ; Liu, J; Liu, SL; Peng, XP; Xu, XL; Zeng, JL; Zhao, GN, 2023
)
1.63
"Securinine (Sec) is a naturally derived compound separated from the roots of Securinega suffruticosa, which has long been used as a herbal medicine. "( Securinine suppresses osteoclastogenesis and ameliorates inflammatory bone loss.
Cheon, YH; Jeong, DH; Kim, JY; Kwak, SC; Lee, CH; Lee, MS; Yoon, KH, 2020
)
3.44
"L-Securinine is a natural product extracted from the leaves or roots of Securinega suffruticosa Pall Rehd."( Antiproliferative activity and apoptosis-inducing mechanism of L-securinine on human breast cancer MCF-7 cells.
Han, S; Ji, Z; Li, M; Wang, Y; Zhang, G, 2014
)
1.2
"(-)-Securinine (SE) is a major alkaloid found in plant Securinega suffruticosa, which has a wide range of pharmacological activities including anticancer, anti-parasitic and central nervous system stimulating effects, etc. "( Development and validation of LC-MS/MS method for quantitative determination of (-)-securinine in mouse plasma.
Wabuyele, SL; Wald, D; Xu, Y, 2014
)
1.19
"Securinine is a plant-derived alkaloid that has previously been used clinically as a therapeutic for primarily neurological related diseases."( Securinine, a myeloid differentiation agent with therapeutic potential for AML.
Agarwal, MK; Agarwal, ML; Chakrabarti, A; Gupta, K; Ramdeo, R; Rana, S; Roth, BL; Tse, W; Wald, DN, 2011
)
2.53

Effects

Securinine has the ability to kill a variety of human cancer cells, including leukemia as well as prostate, cervical, breast, lung, and colon cancer cells. L-SecurInine has an anti-tumor effect against colon cancer SW480 cell.

ExcerptReferenceRelevance
"L-Securinine has an anti-tumor effect against colon cancer SW480 cell. "( L-securinine induced the human colon cancer SW480 cell autophagy and its molecular mechanism.
Cheng, CR; Ji, ZN; Wang, Y; Xia, YH; Yao, SY; Zhang, Q, 2011
)
1.81
"New securinine analogues have been prepared by semisynthesis. "( Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
Ayad, T; Fahy, J; Maillos, P; Perez, M; Poughon, V; Ratovelomanana-Vidal, V, 2016
)
1.23
"Securinine has long been used to treat central nervous system diseases."( Potential anticancer activities of securinine and its molecular targets.
Chen, QX; Fan, XD; Jiang, JG; Liu, CJ; Zhu, W, 2022
)
1.72
"Securinine has the ability to kill a variety of human cancer cells, including, leukemia as well as prostate, cervical, breast, lung, and colon cancer cells. "( Potential anticancer activities of securinine and its molecular targets.
Chen, QX; Fan, XD; Jiang, JG; Liu, CJ; Zhu, W, 2022
)
2.44
"L-Securinine has an anti-tumor effect against colon cancer SW480 cell. "( L-securinine induced the human colon cancer SW480 cell autophagy and its molecular mechanism.
Cheng, CR; Ji, ZN; Wang, Y; Xia, YH; Yao, SY; Zhang, Q, 2011
)
1.81
"Securinine has minimal toxicity in vivo, suggesting it or structurally similar compounds may represent novel, therapeutic adjuvants, which increase resistance to intracellular pathogens."( Securinine, a GABAA receptor antagonist, enhances macrophage clearance of phase II C. burnetii: comparison with TLR agonists.
Jutila, M; Lubick, K; Radke, M, 2007
)
2.5

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolizines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency18.23880.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency8.52530.000221.22318,912.5098AID743035; AID743042; AID743054; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency4.25270.000214.376460.0339AID720692
pregnane X nuclear receptorHomo sapiens (human)Potency31.62280.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency24.79640.000229.305416,493.5996AID743069; AID743079; AID743080; AID743091
67.9K proteinVaccinia virusPotency14.12540.00018.4406100.0000AID720579; AID720580
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency19.07390.001019.414170.9645AID743094; AID743140
aryl hydrocarbon receptorHomo sapiens (human)Potency29.01450.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency13.33320.001723.839378.1014AID743083
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency25.11890.10009.191631.6228AID1346983
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency7.79680.000323.4451159.6830AID743065; AID743067
Cellular tumor antigen p53Homo sapiens (human)Potency29.84930.002319.595674.0614AID651631
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency6.68240.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency6.68240.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (141)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (26)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (63)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID312026Cytotoxicity against mouse L1210 cells2007Journal of natural products, Dec, Volume: 70, Issue:12
Securinega alkaloids from the wood of Securinega suffruticosa var. amamiensis.
AID1517898Reversal of P-gp mediated multidrug resistance in human MCF7/ADM cells assessed as potentiation of doxorubicin-induced cell growth inhibition at 10 uM measured after 48 hrs by MTT assay (Rvb = 5%)2019European journal of medicinal chemistry, Dec-01, Volume: 183Novel virosecurinine bivalent mimetics as potent reversal agents against P-glycoprotein-mediated multidrug resistance.
AID1902907Cytotoxicity against human HL-60 cells assessed as cell viability at 10 uM relative to control2022Bioorganic & medicinal chemistry, 03-15, Volume: 58Structure simplification of the Securinine skeleton reveals the importance of BCD ring system for the cytotoxic activity on HCT116 and HL60 cell lines.
AID1305255Metabolic stability in mouse liver microsomes at 2 uM after 1 hr by ZQ-LC-MS analysis2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID1525277Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Securinega Alkaloids from the Twigs of Securinega suffruticosa and Their Biological Activities.
AID1275510Cytotoxicity against human A549 cells after 72 hrs by Coulter counter analysis2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and biological evaluation of new securinine analogues as potential anticancer agents.
AID1275502Cytotoxicity against human A375 cells assessed as growth inhibition after 72 hrs by ATPlite assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and biological evaluation of new securinine analogues as potential anticancer agents.
AID1902908Cytotoxicity against human HL-60 cells assessed as cell viability at 1 uM relative to control2022Bioorganic & medicinal chemistry, 03-15, Volume: 58Structure simplification of the Securinine skeleton reveals the importance of BCD ring system for the cytotoxic activity on HCT116 and HL60 cell lines.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1305252Metabolic stability in mouse plasma at 5 uM after 2 hrs by ZQ-LC-MS analysis2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID1326613Growth inhibition of human HeLa cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Novel securinine derivatives as topoisomerase I based antitumor agents.
AID1275508Stability in human plasma at 5 uM after 120 mins by LC-MS analysis2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and biological evaluation of new securinine analogues as potential anticancer agents.
AID1902906Cytotoxicity against human HCT-116 cells assessed as cell viability at 1 uM relative to control2022Bioorganic & medicinal chemistry, 03-15, Volume: 58Structure simplification of the Securinine skeleton reveals the importance of BCD ring system for the cytotoxic activity on HCT116 and HL60 cell lines.
AID1525278Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Securinega Alkaloids from the Twigs of Securinega suffruticosa and Their Biological Activities.
AID1326611Antiproliferative activity against human SW480 cells after 48 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Novel securinine derivatives as topoisomerase I based antitumor agents.
AID1305247Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID1326609Inhibition of DNA topoisomerase 1 (unknown origin) assessed as reduction in relaxation of supercoiled pBR322 plasmid DNA at 100 uM incubated for 30 mins by agarose gel electrophoresis relative to control2016European journal of medicinal chemistry, Oct-21, Volume: 122Novel securinine derivatives as topoisomerase I based antitumor agents.
AID1275504Cytotoxicity against human HCT116 cells assessed as growth inhibition at 10 uM after 72 hrs by ATPlite assay relative to control2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and biological evaluation of new securinine analogues as potential anticancer agents.
AID1275506Stability in rat plasma at 5 uM after 120 mins by LC-MS analysis2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and biological evaluation of new securinine analogues as potential anticancer agents.
AID1305249Antiproliferative activity against human MCF7 cells by CCK8 assay2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID1275499Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by ATPlite assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and biological evaluation of new securinine analogues as potential anticancer agents.
AID1525279Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Securinega Alkaloids from the Twigs of Securinega suffruticosa and Their Biological Activities.
AID1525275Cytotoxicity against human A549 cells after 48 hrs by SRB assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Securinega Alkaloids from the Twigs of Securinega suffruticosa and Their Biological Activities.
AID1305243Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability at 20 uM after 72 hrs by ATPlite assay2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID1275503Cytotoxicity against human HCT116 cells assessed as growth inhibition at 20 uM after 72 hrs by ATPlite assay relative to control2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and biological evaluation of new securinine analogues as potential anticancer agents.
AID1305244Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability at 10 uM after 72 hrs by ATPlite assay2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID72300Displacement of [3H]GABA from gamma-aminobutyric-acid A (GABA-A) receptor1992Journal of medicinal chemistry, May-29, Volume: 35, Issue:11
Structure and molecular modeling of GABAA receptor antagonists.
AID1275500Cytotoxicity against human HL60 cells assessed as growth inhibition after 72 hrs by ATPlite assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and biological evaluation of new securinine analogues as potential anticancer agents.
AID1305253Metabolic stability in human plasma at 5 uM after 2 hrs by ZQ-LC-MS analysis2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID1275507Stability in mouse plasma at 5 uM after 120 mins by LC-MS analysis2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and biological evaluation of new securinine analogues as potential anticancer agents.
AID312025Cytotoxicity against human KB cells2007Journal of natural products, Dec, Volume: 70, Issue:12
Securinega alkaloids from the wood of Securinega suffruticosa var. amamiensis.
AID1525282Cytotoxicity against rat C6 cells assessed as cell viability at 20 uM after 24 hrs by MTT assay relative to control2019Journal of natural products, 05-24, Volume: 82, Issue:5
Securinega Alkaloids from the Twigs of Securinega suffruticosa and Their Biological Activities.
AID1275501Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by ATPlite assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and biological evaluation of new securinine analogues as potential anticancer agents.
AID1305256Metabolic stability in human liver microsomes at 2 uM after 1 hr by ZQ-LC-MS analysis2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID1305254Metabolic stability in rat liver microsomes at 2 uM after 1 hr by ZQ-LC-MS analysis2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID1275509Cytotoxicity against human MCF7 cells assessed as growth inhibition by CCK8 assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and biological evaluation of new securinine analogues as potential anticancer agents.
AID1902905Cytotoxicity against human HCT-116 cells assessed as cell viability at 10 uM relative to control2022Bioorganic & medicinal chemistry, 03-15, Volume: 58Structure simplification of the Securinine skeleton reveals the importance of BCD ring system for the cytotoxic activity on HCT116 and HL60 cell lines.
AID1305242Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1326616Growth inhibition of human SH-SY5Y cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Novel securinine derivatives as topoisomerase I based antitumor agents.
AID1525280Cytotoxicity against mouse BV2 cells assessed as cell viability at 20 uM after 24 hrs by MTT assay relative to control2019Journal of natural products, 05-24, Volume: 82, Issue:5
Securinega Alkaloids from the Twigs of Securinega suffruticosa and Their Biological Activities.
AID1326615Growth inhibition of human HepG2 cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Novel securinine derivatives as topoisomerase I based antitumor agents.
AID1525281Neuroprotective activity in rat C6 cells assessed as NGF secretion at 20 uM after 24 hrs by ELISA relative to control2019Journal of natural products, 05-24, Volume: 82, Issue:5
Securinega Alkaloids from the Twigs of Securinega suffruticosa and Their Biological Activities.
AID1902910Cytotoxicity against human HL-60 cells assessed as reduction in cell viability2022Bioorganic & medicinal chemistry, 03-15, Volume: 58Structure simplification of the Securinine skeleton reveals the importance of BCD ring system for the cytotoxic activity on HCT116 and HL60 cell lines.
AID1305251Metabolic stability in rat plasma at 5 uM after 2 hrs by ZQ-LC-MS analysis2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID1326612Growth inhibition of human A549 cells after 72 hrs by MTT assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Novel securinine derivatives as topoisomerase I based antitumor agents.
AID1305246Antiproliferative activity against human A375 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID1525276Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay2019Journal of natural products, 05-24, Volume: 82, Issue:5
Securinega Alkaloids from the Twigs of Securinega suffruticosa and Their Biological Activities.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1517881Reversal of P-gp mediated multidrug resistance in human HepG2/Dox cells assessed as potentiation of doxorubicin-induced cell growth inhibition at 10 uM measured after 48 hrs by MTT assay (Rvb = 24%)2019European journal of medicinal chemistry, Dec-01, Volume: 183Novel virosecurinine bivalent mimetics as potent reversal agents against P-glycoprotein-mediated multidrug resistance.
AID1506602Inhibition of calf thymus topoisomerase 1 assessed as suppression of relaxation of supercoiled pBR322 DNA at 100 uM incubated for 0.5 hrs by bromophenol blue and xylene cyanol FF staining based electrophoresis method2017MedChemComm, Feb-01, Volume: 8, Issue:2
Novel bivalent securinine mimetics as topoisomerase I inhibitors.
AID1902909Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability2022Bioorganic & medicinal chemistry, 03-15, Volume: 58Structure simplification of the Securinine skeleton reveals the importance of BCD ring system for the cytotoxic activity on HCT116 and HL60 cell lines.
AID1305250Antiproliferative activity against human A549 cells2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID1305248Antiproliferative activity against human HL60 cells assessed as reduction in cell viability after 72 hrs by ATPlite assay2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID1305245Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability at 1 uM after 72 hrs by ATPlite assay2016ACS medicinal chemistry letters, Apr-14, Volume: 7, Issue:4
Synthesis and Antiproliferative and Metabolic Evaluations of Novel Securinine Derivatives.
AID1275505Cytotoxicity against human HCT116 cells assessed as growth inhibition at 1 uM after 72 hrs by ATPlite assay relative to control2016European journal of medicinal chemistry, Feb-15, Volume: 109Synthesis and biological evaluation of new securinine analogues as potential anticancer agents.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (95)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (22.11)18.7374
1990's7 (7.37)18.2507
2000's20 (21.05)29.6817
2010's37 (38.95)24.3611
2020's10 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.48 (24.57)
Research Supply Index4.62 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index39.41 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.01%)5.53%
Reviews5 (5.05%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other93 (93.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]